FDA approves Mozobil (plerixafor) for multiple myeloma or non-Hodgkin’s lymphomas
Dr. Margaret Chan, WHO Director-General says a major milestone in the long struggle against HIV/AIDS has been reached. This year is the 20th anniversary of the emergence of the devastating disease and Dr. Chan says more than 3 million people in low and middle-income countries are now receiving life-prolonging antiretroviral therapy - an achievement which
Full Post: WHO boss says major milestone reached in fight against AIDS
The U.S. Food and Drug Administration has approved Mozobil (plerixafor), a drug that helps increase the number of blood stem cells for bone marrow transplantation in patients with certain forms of blood cancer.
Mozobil is intended to be used in combination with the growth factor granulocyte-colony stimulating factor (G-CSF), for treatment of adults with multiple myeloma or non-Hodgkin’s lymphomas. Multiple myeloma is cancer of the plasma cell, a cell in the bone marrow that produces antibodies to help fight infection and disease. Non-Hodgkin lymphomas are a diverse group of blood cell cancers derived from lymphocytes, a type of white blood cell.
Prior to receiving high-dose chemotherapy or radiation therapy, patients with these forms of cancer sometimes undergo a procedure known as apheresis in which blood stem cells are collected and stored for reinfusion after therapy. G-CSF is commonly administered to help release and collect stem cells from the bone marrow. Mozobil is an injectable drug that, when used in combination with G-CSF, boosts the number of stem cells released from the bone marrow into the blood stream.
“Collecting the millions of cells needed for a bone marrow transplant can take hours or days,” said Richard Pazdur, M.D., director, Office of Oncology Drug Products, Center for Drug Evaluation and Research, FDA. “Mobozil provides a new therapeutic option for patients with certain types of blood cancers by increasing the number of stem cells collected in a given time period to be reinfused after therapy.”
In two randomized clinical trials - one in patients with non-Hodgkin’s lymphoma, the other with multiple myeloma - Mozobil combined with G-CSF increased the number of stem cells available for collection and transplantation compared with patients receiving G-CSF alone.
The most commonly reported adverse reactions in these trials and other smaller studies were diarrhea, nausea, fatigue, injection site reactions, headaches, joint pain, dizziness and vomiting.
Mozobil is manufactured by Genzyme Corp., Cambridge, Mass.
Scientists have tricked bone marrow into releasing extra adult stem cells into the bloodstream, a technique that they hope could one day be used to repair heart damage or mend a broken bone, in a new study published today in the journal Cell Stem Cell. When a person has a disease or an injury, the
Full Post: Researchers trick bone marrow into releasing mesenchymal stem cells
Kiadis Pharma has announced that the U.S. Food and Drug Administration (FDA) has granted its product Reviroc Orphan Drug Designations (ODD) for the treatment of two types of Non-Hodgkin Lymphoma (NHL). One ODD has been granted for diffuse large B-cell lymphoma and the other one for the treatment of follicular lymphoma. Reviroc(TM) is under development
Full Post: Kiadis Pharma receives two orphan drug designations for Reviroc
Taking blood stem cells collected from an umbilical cord into the lab and expanding their number before transplanting them to replace a patient’s blood supply is as safe as a standard cord blood transplant, researchers reported at the 50th Annual Meeting of the American Society of Hematology. In a first-of-its-kind randomized clinical trial, researchers at
Full Post: Trial shows safety of pre-transplant expansion of umbilical cord blood stem cells
Investigators at Children’s Research Institute, BloodCenter of Wisconsin’s Blood Research Institute and the Medical College of Wisconsin have discovered a new way to help the blood clot by having the missing clotting factor packaged in the patient’s own platelets. In the October 2008 edition of Blood, investigators describe how a gene-modified bone marrow transplant can
Full Post: A new method to control bleeding in hemophilia
Investigators from Massachusetts General Hospital (MGH) have found a subpopulation of hematopoietic stem cells, the source of all blood and immune system cells, that reproduce much more slowly than previously anticipated. Use of these cells may improve the outcome of stem cell transplants - also called bone marrow transplants - for the treatment of leukemia
Full Post: Hematopoietic stem cells found to reproduce more slowly than expected